{"id":"NCT03371108","sponsor":"Gan and Lee Pharmaceuticals, USA","briefTitle":"Gan & Lee Insulin Glargine Target Type (2) Evaluating Research","officialTitle":"AN OPEN-LABEL, RANDOMIZED, MULTICENTER, PHASE 3 STUDY TO COMPARE THE IMMUNOGENICITY, EFFICACY, AND SAFETY OF GAN & LEE PHARMACEUTICALS INSULIN GLARGINE INJECTION TO LANTUS® IN ADULT SUBJECTS WITH TYPE 2 DIABETES MELLITUS","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-10-31","primaryCompletion":"2019-04-17","completion":"2019-04-17","firstPosted":"2017-12-13","resultsPosted":"2022-03-23","lastUpdate":"2022-04-01"},"enrollment":567,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes Mellitus, Type 2"],"interventions":[{"type":"BIOLOGICAL","name":"Gan & Lee Insulin Glargine Injection","otherNames":[]},{"type":"BIOLOGICAL","name":"Lantus®","otherNames":[]}],"arms":[{"label":"Gan & Lee Insulin Glargine Injection","type":"EXPERIMENTAL"},{"label":"Lantus®","type":"ACTIVE_COMPARATOR"}],"summary":"Primary Objective:\n\n• To evaluate equivalence of Gan \\& Lee Insulin Glargine Injection and Lantus® in terms of immunogenicity\n\nSecondary Objective:\n\nImmunogenicity:\n\n• To evaluate the percentage of subjects with negative anti-insulin antibodies (AIA) at baseline who develop confirmed positive AIA up to Week 26, the percentage of subjects with at least a 4-fold increase in titers compared to baseline value, mean change from baseline in AIA titers between treatment groups, the percentage of subjects with confirmed positive AIA who develop any anti-insulin neutralizing antibodies up to visit Week 26, and the percentage of subjects in each treatment group with confirmed positive AIA up to visit Week 26\n\nSafety:\n\n• To evaluate the safety of Gan \\& Lee Insulin Glargine Injection in comparison with that of Lantus®\n\nEfficacy:\n\n• To evaluate the efficacy of Gan \\& Lee Insulin Glargine Injection in comparison with that of Lantus®","primaryOutcome":{"measure":"Treatment-induced Anti-Insulin Antibody (TI-AIA) is the Primary Endpoint","timeFrame":"Baseline to Week 26","effectByArm":[{"arm":"Gan & Lee Insulin Glargine Injection","deltaMin":54,"sd":null},{"arm":"Lantus®","deltaMin":60,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":57,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":15,"n":281},"commonTop":["Hypoglycemia","Headache","Weight Increased","Dizziness","Fatigue"]}}